Velaglucerase beta

维拉苷酶β

Report date: 2026/02/11 20:01:36

Base Information

Drug NameVelaglucerase beta
Drug Alias NameGlucocerebrosidase (CANbridge)戈芮宁GaurunningCAN-103
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionBeta-glucocerebrosidase replacements
TargetsBeta-glucocerebrosidase
Therapy Area/IndicationsGaucher's disease type IIIGaucher's disease type ILysosomal Storage Diseases +[4] 
Global Approved IndicationsGaucher's disease type IIIGaucher's disease type I
Approved Indications in ChinaGaucher's disease type IIIGaucher's disease type I
Original Approved Country/TerritoryMainland China
Original Approved Date2025/05/13
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBeihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCANbridge (Suzhou) Bio-pharma Co LtdWuxi Apptec Co LtdBeihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsGaucher's disease type IIIGaucher's disease type ILysosomal Storage Diseases +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A